Arianna Kousari1, Carlee Moser2, Maxine Olefsky2, Todd T Brown1, Judith S Currier3, Grace A McComsey4, Ann Scherzinger5, James H Stein6, Jordan E Lake7, Kristine M Erlandson1. 1. Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO. 2. Harvard T.H. Chan School of Public Health, Boston, MA. 3. Department of Medicine, University of California Los Angeles, Los Angeles, CA. 4. Departments of Medicine and Pediatrics, Case Western Reserve, Cleveland, OH. 5. Department of Radiology, University of Colorado Anschutz Medical Campus, Aurora, CO. 6. Department of Medicine, University of Wisconsin, Madison, WI; and. 7. Department of Medicine, University of Texas Houston, Houston, TX.
Abstract
BACKGROUND: We have previously shown that the initiation of antiretroviral therapy (ART) is associated with a decrease in skeletal muscle density (greater fat accumulation), suggesting that gains in lean body mass seen in many ART studies may reflect gains in low quality, fatty muscle. Here, we explore whether skeletal muscle density and area are associated with markers of inflammation and immune activation. METHODS: ART-naïve people with HIV were randomized to raltegravir or ritonavir-boosted atazanavir or darunavir, each with tenofovir disoproxil fumarate/emtricitabine. Abdominal computed tomography scans from baseline and week 96 were reanalyzed for psoas density and area and correlations explored with inflammation [interleukin-6 (IL-6) and high-sensitivity C-reactive protein] and immune activation [soluble CD14 (sCD14), soluble CD163 (sCD163), and %CD38+HLADR+ on CD4+ or CD8+ T cells]. RESULTS: Two hundred twenty-two participants had available inflammation/immune activation markers and paired computed tomography scans. At baseline, lower psoas density (greater fat) correlated with higher IL-6 (r = -0.26, P < 0.001) and sCD163 (r -0.15, P = 0.03) and lower lean psoas area correlated with higher IL-6, high-sensitivity C-reactive protein, sCD14, sCD163, and %CD38+HLADR+ on CD4+ T cells (r = -0.30-0.13; all P ≤ 0.05). From baseline to week 96, greater percent decrease in total psoas density (more fat) correlated with greater increase in IL-6 (r = -0.14; P = 0.04); greater % decrease in lean psoas area correlated greater increases in IL-6, sCD14, sCD163, and %CD38+HLADR+ on CD8+ T cells (r = -0.15 to -0.18; all P < 0.04). CONCLUSIONS: Greater fat infiltration within the psoas muscle (lower density) and greater loss in lean psoas muscle area were associated with higher inflammation and immune activation, which may portend important effects on muscle function and cardiometabolic risk.
BACKGROUND: We have previously shown that the initiation of antiretroviral therapy (ART) is associated with a decrease in skeletal muscle density (greater fat accumulation), suggesting that gains in lean body mass seen in many ART studies may reflect gains in low quality, fatty muscle. Here, we explore whether skeletal muscle density and area are associated with markers of inflammation and immune activation. METHODS: ART-naïve people with HIV were randomized to raltegravir or ritonavir-boosted atazanavir or darunavir, each with tenofovir disoproxil fumarate/emtricitabine. Abdominal computed tomography scans from baseline and week 96 were reanalyzed for psoas density and area and correlations explored with inflammation [interleukin-6 (IL-6) and high-sensitivity C-reactive protein] and immune activation [soluble CD14 (sCD14), soluble CD163 (sCD163), and %CD38+HLADR+ on CD4+ or CD8+ T cells]. RESULTS: Two hundred twenty-two participants had available inflammation/immune activation markers and paired computed tomography scans. At baseline, lower psoas density (greater fat) correlated with higher IL-6 (r = -0.26, P < 0.001) and sCD163 (r -0.15, P = 0.03) and lower lean psoas area correlated with higher IL-6, high-sensitivity C-reactive protein, sCD14, sCD163, and %CD38+HLADR+ on CD4+ T cells (r = -0.30-0.13; all P ≤ 0.05). From baseline to week 96, greater percent decrease in total psoas density (more fat) correlated with greater increase in IL-6 (r = -0.14; P = 0.04); greater % decrease in lean psoas area correlated greater increases in IL-6, sCD14, sCD163, and %CD38+HLADR+ on CD8+ T cells (r = -0.15 to -0.18; all P < 0.04). CONCLUSIONS: Greater fat infiltration within the psoas muscle (lower density) and greater loss in lean psoas muscle area were associated with higher inflammation and immune activation, which may portend important effects on muscle function and cardiometabolic risk.
Authors: John R Koethe; Cathy A Jenkins; Bryan Lau; Bryan E Shepherd; Amy C Justice; Janet P Tate; Kate Buchacz; Sonia Napravnik; Angel M Mayor; Michael A Horberg; Aaron J Blashill; Amanda Willig; C William Wester; Michael J Silverberg; John Gill; Jennifer E Thorne; Marina Klein; Joseph J Eron; Mari M Kitahata; Timothy R Sterling; Richard D Moore Journal: AIDS Res Hum Retroviruses Date: 2015-09-09 Impact factor: 2.205
Authors: Melissa Herrin; Janet P Tate; Kathleen M Akgün; Adeel A Butt; Kristina Crothers; Matthew S Freiberg; Cynthia L Gibert; David A Leaf; David Rimland; Maria C Rodriguez-Barradas; Chris B Ruser; Kevan C Herold; Amy C Justice Journal: J Acquir Immune Defic Syndr Date: 2016-10-01 Impact factor: 3.731
Authors: Y Rolland; S Czerwinski; G Abellan Van Kan; J E Morley; M Cesari; G Onder; J Woo; R Baumgartner; F Pillard; Y Boirie; W M C Chumlea; B Vellas Journal: J Nutr Health Aging Date: 2008 Aug-Sep Impact factor: 4.075
Authors: Kristine M Erlandson; Amanda A Allshouse; Catherine M Jankowski; Eric J Lee; Kevin M Rufner; Brent E Palmer; Cara C Wilson; Samantha MaWhinney; Wendy M Kohrt; Thomas B Campbell Journal: J Infect Dis Date: 2013-04-04 Impact factor: 5.226
Authors: Anne Langkilde; Janne Petersen; Jens Henrik Henriksen; Frank Krieger Jensen; Jan Gerstoft; Jesper Eugen-Olsen; Ove Andersen Journal: Immun Ageing Date: 2015-08-04 Impact factor: 6.400